Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shanghai Haohai Biological Technology Co., Ltd.*
上海昊海生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6826)

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made by Shanghai Haohai Biological Technology Co., Ltd.* (the "**Company**") pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

References are made to the resolutions regarding the granting of a general mandate to the board of directors (the "**Board**") of the Company to repurchase the H Shares approved at the Company's 2023 annual general meeting, the 2024 first A shareholders' class meeting and the 2024 first H shareholders' class meeting convened on 29 May 2024 (the "**2024 Repurchase Mandate**"), and the resolutions regarding the granting of a general mandate to the Board to repurchase the H Shares approved at the Company's 2024 annual general meeting, the 2025 first A shareholders' class meeting and the 2025 first H shareholders' class meeting convened on 10 June 2025 (the "**2025 Repurchase Mandate**").

As of the date of this announcement, 612,600 H Shares repurchased by the Company during the period from 5 December 2024 to 12 May 2025 under the 2024 Repurchase Mandate, and the 2,600,200 H Shares repurchased during the period from 15 September 2025 to 29 December 2025 under the 2025 Repurchase Mandate have all been cancelled.

Upon completion of the cancellation of the aforementioned total of 3,212,800 H Shares, the total number of shares of the Company has changed from 233,193,695 shares to 229,980,895 shares, and the registered capital of the Company has changed from RMB233,193,695 to RMB229,980,895. Based on such changes in the total number of shares and registered capital of the Company, a meeting of the Board is held to consider and approve the proposal to change the registered capital and amend the Articles of Association on 20 March 2026. Pursuant to the 2024 Repurchase Mandate and the 2025 Repurchase Mandate, the Board was also authorized to carry out cancellation procedures for the repurchased shares, reduce registered capital, make corresponding amendments to the Articles of Association in respect of the changes in the total share capital and shareholding structure, etc., and to carry out relevant statutory registrations and filing procedures within and outside the People's Republic of China. In view of the above, the amendments to the Articles of Association will not be submitted for consideration and approval at the shareholders' meeting of the Company, and shall become effective on 20 March 2026.

The amendments to the Articles of Association are set out as follows:

No.	Existing Articles	Revised Articles
1	**Article 18** Upon establishment of the Company, as approved by the securities regulatory authorities under the State Council and the Hong Kong Stock Exchange, the Company issued 40, 045, 300 ordinary shares through initial public offering, all are H shares. Upon completion of the aforesaid issue of H shares, the capital structure of the Company: total share capital is 160,045,300 shares, of which 120,000,000 are A shares, representing 74.979% of ordinary share capital of the Company, and 40,045,300 are H shares, representing 25.021% of ordinary share capital of the Company. On 27 September 2019, approved by the CSRC (Zheng Jian Xu Ke [2019] No. 1793), the Company initially public offered 17,800,000 Domestic Shares, such Domestic Shares issued and issued previous by the Company are listed on 30 October 2019. Upon completion of the aforesaid issue of A shares, the capital structure of the Company: total share capital is 177,845,300 shares, of which 137,800,000 are A shares, representing 77.483% of ordinary shares capital of the Company, 40,045,300 are H shares, representing 22.517% of ordinary shares capital of the Company. The current total number of shares of the Company is 233,193,695, of which 194,051,855 are A shares, representing 83.215% of ordinary share capital of the Company, and 39,141,840 are H shares, representing 16.785% of ordinary share capital of the Company.	**Article 18** Upon establishment of the Company, as approved by the securities regulatory authorities under the State Council and the Hong Kong Stock Exchange, the Company issued 40, 045, 300 ordinary shares through initial public offering, all are H shares. Upon completion of the aforesaid issue of H shares, the capital structure of the Company: total share capital is 160,045,300 shares, of which 120,000,000 are A shares, representing 74.979% of ordinary share capital of the Company, and 40,045,300 are H shares, representing 25.021% of ordinary share capital of the Company. On 27 September 2019, approved by the CSRC (Zheng Jian Xu Ke [2019] No. 1793), the Company initially public offered 17,800,000 Domestic Shares, such Domestic Shares issued and issued previous by the Company are listed on 30 October 2019. Upon completion of the aforesaid issue of A shares, the capital structure of the Company: total share capital is 177,845,300 shares, of which 137,800,000 are A shares, representing 77.483% of ordinary shares capital of the Company, 40,045,300 are H shares, representing 22.517% of ordinary shares capital of the Company. The current total number of shares of the Company is 229,980,895, of which 194,051,855 are A shares, representing 84.377% of ordinary share capital of the Company, and 35,929,040 are H shares, representing 15.623% of ordinary share capital of the Company.
2	**Article 19** The registered capital of the Company is RMB233,193,695.	**Article 19** The registered capital of the Company is RMB229,980,895.

Save for the above amendments to the Articles of Association, other provisions of the Articles of Association remain unchanged. The English version of the above amendments to the Articles of Association is an unofficial translation of its Chinese version. In case of any discrepancies, the Chinese version shall prevail.

By order of the Board
Shanghai Haohai Biological Technology Co., Ltd.*
Hou Yongtai
Chairman

Shanghai, the PRC, 20 March 2026

As at the date of this announcement, the executive Directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive Directors of the Company are Ms. You Jie, Mr. Huang Ming and Mr. Wei Changzheng; and the independent non-executive Directors are Mr. Shen Hongbo, Mr. Jiang Zhihong, Mr. Su Zhi and Mr. Yang Yushe.

* *For identification purpose only*